© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 14, 1036-1038,
July 16, 2003
© 2003 Oxford University Press
NEWS |
Research Retreat: Pfizer Eliminates Sugen, Shrinks Cancer Infrastructure
| The first 10% of the full text of this article appears below. |
Four years ago, Sugen Inc. chief executive officer Stephen Evans-Freke painted a rosy picture of his biotechnology companys future. "Were fortunate in being the world leader ... in signal transduction-based drug discovery," Evans-Freke said, speaking at a health care conference. "We think we can make an awful lot of money for our stockholders over the next 2 to 3 years."
Within a year of making that statement, Evans-Freke had departed, and Sugen had ceased to be an independent company, absorbed into Pharmacia & UpJohn. Now Sugen, based in South San Francisco, will vanish completely, a casualty of the $57 billion Pfizer-Pharmacia merger, completed April 16. "Most of the employees will sort of disappear, they will go to other companies," predicted Sugen co-founder Axel Ullrich,
A Biotech Pioneers Rise and Fall
Pfizer Takes Over